Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,107 Mln
P/E Ratio
--
P/B Ratio
2.29
Industry P/E
--
Debt to Equity
0.03
ROE
-0.48 %
ROCE
-46.71 %
Div. Yield
0 %
Book Value
9.88
EPS
-3.97
CFO
$-469.78 Mln
EBITDA
$-610.70 Mln
Net Profit
$-687.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Viridian Therapeutics (VRDN)
| -31.25 | -8.73 | -31.39 | 2.33 | -1.99 | 5.12 | -29.57 |
|
BSE Sensex*
| 2.51 | 3.61 | 4.50 | 7.42 | 12.02 | 19.64 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Viridian Therapeutics (VRDN)
| -11.89 | -25.44 | 47.75 | 20.18 | 128.52 | -84.16 | -70.75 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor... that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Address: 221 Crescent Street, Waltham, MA, United States, 02453 Read more
CEO, President & Director
Mr. Stephen F. Mahoney J.D., MBA
CEO, President & Director
Mr. Stephen F. Mahoney J.D., MBA
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Viridian Therapeutics Inc (VRDN) stood at $ 742 Mln as on 31-Dec-24
The share price of Viridian Therapeutics Inc (VRDN) is $13.18 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Viridian Therapeutics Inc (VRDN) has given a return of -1.99% in the last 3 years.
Viridian Therapeutics Inc (VRDN) has a market capitalisation of $ 1,107 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Viridian Therapeutics Inc (VRDN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Viridian Therapeutics Inc (VRDN) and enter the required number of quantities and click on buy to purchase the shares of Viridian Therapeutics Inc (VRDN).
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Address: 221 Crescent Street, Waltham, MA, United States, 02453
The CEO & director of Mr. Stephen F. Mahoney J.D., MBA. is Viridian Therapeutics Inc (VRDN), and CFO & Sr. VP is Mr. Stephen F. Mahoney J.D., MBA.
There is no promoter pledging in Viridian Therapeutics Inc (VRDN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Viridian Therapeutics Inc. (VRDN) | Ratios |
|---|---|
|
Return on equity(%)
|
-48.48
|
|
Operating margin(%)
|
-88378.48
|
|
Net Margin(%)
|
-89387.09
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Viridian Therapeutics Inc (VRDN) was $0 Mln.
$-0.35
(
